Division of Gynecologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Clin Adv Hematol Oncol. 2024 Jul-Aug;22(6):301-310.
Endometrial cancer, including high-grade subtypes, has a rising incidence and mortality. Uterine serous carcinoma (USC) and uterine carcinosarcoma (UCS) make up a small but increasing proportion of endometrial cancer cases and account for a significant portion of endometrial cancer mortality. Despite being molecularly and clinically distinct, both USC and UCS have a poor prognosis. Thus far, there have been few therapeutic strategies directed at these endometrial cancer subtypes. This review summarizes the genomic and molecular features of USC and UCS, clinical advances in the treatment of primary advanced and recurrent endometrial cancer, and novel molecularly-driven treatment strategies.
子宫内膜癌，包括高级别亚型，其发病率和死亡率呈上升趋势。子宫浆液性癌（USC）和子宫癌肉瘤（UCS）在子宫内膜癌病例中占比较小，但呈上升趋势，占子宫内膜癌死亡人数的很大一部分。尽管 USC 和 UCS 在分子和临床上有明显区别，但它们的预后都很差。到目前为止，针对这些子宫内膜癌亚型的治疗策略很少。本综述总结了 USC 和 UCS 的基因组和分子特征、原发性晚期和复发性子宫内膜癌治疗方面的临床进展，以及新的分子驱动的治疗策略。
